| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
The Annals of Thoracic Surgery, Vol 58, 421-424, Copyright © 1994 by The Society of Thoracic Surgeons
M Pekna, L Hagman, E Halden, UR Nilsson, B Nilsson and S Thelin
The role of complement in biocompatibility reactions and the correlation
between complement activation during cardiopulmonary bypass (CPB) and
postperfusion syndrome have inspired attempts to improve the
biocompatibility of extracorporeal blood oxygenation devices. Here we
assessed the effect of immobilized heparin on the generation of C3a and
terminal complement complexes during CPB. Thirty patients undergoing
aortocoronary bypass were randomized to CPB with either heparin-coated
(Duraflo II; Bentley, Irvine, CA) or noncoated control membrane oxygenators
(Univox; Bentley). A standard dose of heparin (300 IU/kg) was given to the
control group while the heparin dose was reduced to 30% (100 IU/kg) in the
heparin-coated group. Significantly lower levels of terminal complement
complexes were detected in the heparin-coated group by the end of CPB. From
28 +/- 5 AU/mL (heparin-coated group) and 26 +/- 3 AU/mL (control group,
mean +/- standard error of the mean) the terminal complement complex levels
increased to 391 +/- 35 AU/mL and 602 +/- 47 AU/mL, respectively (p <
0.002). This difference was still apparent 180 minutes after CPB. Although
there was no difference in C3a levels between the two groups at the end of
CPB, C3a levels were significantly lower in the heparin-coated group 30
minutes after CPB (194 +/- 18 ng/mL and 307 +/- 18 ng/mL in heparin-coated
and control groups, respectively; p < 0.001). We conclude that the
heparin-coated surface is more biocompatible with regard to complement
activation than is the ordinary unmodified surface in extracorporeal
circuits.
ARTICLES
Complement activation during cardiopulmonary bypass: effects of immobilized heparin
Department of Clinical Immunology and Transfusion Medicine, University Hospital, Uppsala, Sweden.
This article has been cited by other articles:
|
|
 |
|
  O. Mangoush, S. Purkayastha, S. Haj-Yahia, J. Kinross, M. Hayward, F. Bartolozzi, A. Darzi, and T. Athanasiou Heparin-bonded circuits versus nonheparin-bonded circuits: an evaluation of their effect on clinical outcomes Eur. J. Cardiothorac. Surg., June 1, 2007; 31(6): 1058 - 1069. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. Khoshbin, A. E. Dux, H. Killer, A. W Sosnowski, R. K Firmin, and G. J Peek A comparison of radiographic signs of pulmonary inflammation during ECMO between silicon and poly-methyl pentene oxygenators Perfusion, January 1, 2007; 22(1): 15 - 21. [Abstract] [PDF]
|
|
|
|
|
|
E. Khoshbin, C. Westrope, S. Pooboni, D. Machin, H. Killer, G. J Peek, A. W Sosnowski, and R. K Firmin Performance of polymethyl pentene oxygenators for neonatal extracorporeal membrane oxygenation: a comparison with silicone membrane oxygenators Perfusion, May 1, 2005; 20(3): 129 - 134. [Abstract] [PDF]
|
|
|
|
 |
|
 F. D. Rubens and T. Mesana Surface Modified Cardiopulmonary Bypass Circuits: Modifying the Inflammatory Response Seminars in Cardiothoracic and Vascular Anesthesia, December 1, 2002; 6(4): 301 - 306. [Abstract] [PDF]
|
|
|
|
|
|
Y. Fromes, D. Gaillard, O. Ponzio, M. Chauffert, M.-F. Gerhardt, P. Deleuze, and O. M. Bical Reduction of the inflammatory response following coronary bypass grafting with total minimal extracorporeal circulation Eur. J. Cardiothorac. Surg., October 1, 2002; 22(4): 527 - 533. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. S. Aldea, L. O. Soltow, W. L. Chandler, C. M. Triggs, C. R. Vocelka, G. I. Crockett, Y. T. Shin, W. E. Curtis, and E. D. Verrier Limitation of thrombin generation, platelet activation, and inflammation by elimination of cardiotomy suction in patients undergoing coronary artery bypass grafting treated with heparin-bonded circuits J. Thorac. Cardiovasc. Surg., April 1, 2002; 123(4): 742 - 755. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Ovrum, G. Tangen, R. Oystese, M. A. L. Ringdal, and R. Istad Comparison of two heparin-coated extracorporeal circuits with reduced systemic anticoagulation in routine coronary artery bypass operations J. Thorac. Cardiovasc. Surg., February 1, 2001; 121(2): 0324 - 330. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. A. Grossi, K. Kallenbach, S. Chau, C. C. Derivaux, M. G. Aguinaga, B. M. Steinberg, D. Kim, S. Iyer, M. Tayyarah, M. Artman, et al. Impact of heparin bonding on pediatric cardiopulmonary bypass: a prospective randomized study Ann. Thorac. Surg., July 1, 2000; 70(1): 191 - 196. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. B. Mahoney and G. M. Lemole Transfusion after coronary artery bypass surgery: the impact of heparin-bonded circuits Eur. J. Cardiothorac. Surg., August 1, 1999; 16(2): 206 - 210. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. M. McCarthy, J.-P. P. Yared, R. C. Foster, D. A. Ogella, J. A. Borsh, and D. M. Cosgrove III A prospective randomized trial of Duraflo II heparin-coated circuits in cardiac reoperations Ann. Thorac. Surg., May 1, 1999; 67(5): 1268 - 1273. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Ranucci, A. Mazzucco, R. Pessotto, G. Grillone, V. Casati, L. Porreca, R. Maugeri, M. Meli, P. Magagna, S. Cirri, et al. Heparin-coated circuits for high-risk patients: a multicenter, prospective, randomized trial Ann. Thorac. Surg., April 1, 1999; 67(4): 994 - 1000. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Baufreton, M. Moczar, L. Intrator, P. G. Jansen, H. te Velthuis, P. Le Besnerais, J. P. Farcet, C. R. Wildevuur, and D. Y Loisance Inflammatory response to cardiopulmonary bypass using two different types of heparin-coated extracorporeal circuits Perfusion, December 1, 1998; 13(6): 419 - 427. [Abstract] [PDF]
|
|
|
|
|
|
C. Baufreton, M. Kirsch, and D. Y. Loisance Measures to control blood activation during assisted circulation Ann. Thorac. Surg., November 1, 1998; 66(5): 1837 - 1844. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. S. Aldea, P. O'Gara, O. M. Shapira, P. Treanor, A. Osman, E. Patalis, C. Arkin, R. Diamond, V. Babikian, H. L. Lazar, et al. Effect of Anticoagulation Protocol on Outcome in Patients Undergoing CABG With Heparin-Bonded Cardiopulmonary Bypass Circuits Ann. Thorac. Surg., February 1, 1998; 65(2): 425 - 433. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Belboul and N. Al-Khaja Does heparin coating improve biocompatibility? A study on complement, blood cells and postoperative morbidity during cardiac surgery Perfusion, December 1, 1997; 12(6): 385 - 391. [Abstract] [PDF]
|
|
|
|
|
|
E. Ovrum, E. A. Holen, G. Tangen, and M.-A. L. Ringdal Heparinized Cardiopulmonary Bypass and Full Heparin Dose Marginally Improve Clinical Performance Ann. Thorac. Surg., October 1, 1996; 62(4): 1128 - 1133. [Abstract] [Full Text]
|
|
|
|
|
|
D. D. Muehrcke, P. M. McCarthy, K. Kottke-Marchant, H. Harasaki, J. Pierre-Yared, J. A. Borsh, D. A. Ogella, and D. M. Cosgrove BIOCOMPATIBILITY OF HEPARIN-COATED EXTRACORPOREAL BYPASS CIRCUITS: A RANDOMIZED, MASKED CLINICAL TRIAL J. Thorac. Cardiovasc. Surg., August 1, 1996; 112(2): 472 - 483. [Abstract] [Full Text]
|
|
|
|
|
|
L.-C. Hsu Biocompatibility in heparin-coated extracorporeal circuits Perfusion, May 1, 1996; 11(3): 256 - 263. [PDF]
|
|
|
|
|
|
P. G. M. Jansen, C. Baufreton, P. Le Besnerais, D. Y. Loisance, and C. R. H. Wildevuur Heparin-Coated Circuits and Aprotinin Prime for Coronary Artery Bypass Grafting Ann. Thorac. Surg., May 1, 1996; 61(5): 1363 - 1366. [Abstract] [Full Text]
|
|
|
|
|
|
V. Ferraris, S. Ferraris, and S. L. H. Edmunds Jr RISK FACTORS FOR POSTOPERATIVE MORBIDITY J. Thorac. Cardiovasc. Surg., April 1, 1996; 111(4): 731 - 741. [Abstract] [Full Text]
|
|
|
|
|
|
E. Ovrum, L. Nilsson, P. Venge, J. W. Borowiec, and S. Thelin Eosinophil Granulocyte Activation and Heparin-Coated Cardiopulmonary Bypass Ann. Thorac. Surg., March 1, 1996; 61(3): 1038 - 1039. [Full Text]
|
|
|
|
|
|
R. C. Gorman, N. P. Ziats, A. K. Rao, N. Gikakis, L. Sun, M. M. H. Khan, N. Stenach, S. Sapatnekar, V. Chouhan, J. H. Gorman III, et al. SURFACE-BOUND HEPARIN FAILS TO REDUCE THROMBIN FORMATION DURING CLINICAL CARDIOPULMONARY BYPASS J. Thorac. Cardiovasc. Surg., January 1, 1996; 111(1): 1 - 12. [Abstract] [Full Text]
|
|
|
|
|
|
E. Ovrum, T. E. Mollnes, E. Fosse, E. A. Holen, G. Tangen, M.-A. L. Ringdal, and V. Videm High and Low Heparin Dose With Heparin-Coated Cardiopulmonary Bypass: Activation of Complement and Granulocytes Ann. Thorac. Surg., December 1, 1995; 60(6): 1755 - 1761. [Abstract] [Full Text]
|
|
|
|
|
|
E. Ovrum, T. E. Mollnes, E. Fosse, E. A. Holen, G. Tangen, M. Abdelnoor, M.-A. L. Ringdal, R. Oystese, and P. Venge COMPLEMENT AND GRANULOCYTE ACTIVATION IN TWO DIFFERENT TYPES OF HEPARINIZED EXTRACORPOREAL CIRCUITS J. Thorac. Cardiovasc. Surg., December 1, 1995; 110(6): 1623 - 1632. [Abstract] [Full Text]
|
|
|
|
|
|
O. Moen, E. Fosse, V. Brockmeier, C. Andersson, T. E. Mollnes, K. Hogasen, and P. Venge Disparity in Blood Activation by Two Different Heparin-Coated Cardiopulmonary Bypass Systems Ann. Thorac. Surg., November 1, 1995; 60(5): 1317 - 1323. [Abstract] [Full Text]
|
|
|
|
|
|
P. G. M. Jansen, H. t. Velthuis, R. A. J. M. Huybregts, R. Paulus, E. R. Bulder, H. I. van der Spoel, P. D. Bezemer, E. H. Slaats, L. Eijsman, and C. R. H. Wildevuur Reduced complement activation and improved postoperative performance after cardiopulmonary bypass with heparin-coated circuits J. Thorac. Cardiovasc. Surg., September 1, 1995; 110(3): 829 - 834. [Abstract] [Full Text]
|
|
|
|
|
|
E. Ovrum, E. A. Holen, G. Tangen, F. Brosstad, M. Abdelnoor, M.-A. L. Ringdal, R. Oystese, and R. Istad Completely Heparinized Cardiopulmonary Bypass and Reduced Systemic Heparin: Clinical and Hemostatic Effects Ann. Thorac. Surg., August 1, 1995; 60(2): 365 - 371. [Abstract] [Full Text]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| ANN THORAC SURG | ASIAN CARDIOVASC THORAC ANN | EUR J CARDIOTHORAC SURG |
| J THORAC CARDIOVASC SURG | ICVTS | ALL CTSNet JOURNALS |
